Post #1049048 795 Sep 30, 2026, 14:16 UTC ELI LILLY: PLANS TO INITIATE PHASE 3 STUDIES OF ELORATZP CO-FORMULATION PRODUCT BY 2026 END USING OPTIMIZED ESCALATION SCHEDULE ...